Treatment of Cardiogenic Shock and Refractory Ventricular Fibrillation: Pulling Out All the Stops

Margaret Mary Glazier1, Amir Kaki2,3

  • 1University of Galway School of Medicine, Galway, Ireland.

Insights

This case study highlights a successful treatment for acute myocardial infarction with cardiogenic shock and refractory ventricular fibrillation using extracorporeal membrane oxygenation (ECMO) and percutaneous coronary intervention. The patient experienced a full recovery, demonstrating the efficacy of this combined approach.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Interventional Cardiology

Background:

  • Acute myocardial infarction (AMI) with cardiogenic shock and refractory ventricular fibrillation (VF) presents a critical medical emergency with high mortality.
  • Prompt and aggressive management strategies are essential for improving patient outcomes in such complex cases.

Observation:

  • A 62-year-old woman presented with acute inferior wall myocardial infarction, cardiogenic shock, and refractory VF.
  • Mechanical circulatory support with venoarterial extracorporeal membrane oxygenation (ECMO) was initiated, followed by right heart catheterization, coronary angiography, and angioplasty.
  • Therapeutic hypothermia was administered post-procedure.

Findings:

  • The patient's ventricular fibrillation resolved, hemodynamic parameters stabilized (MAP >65 mmHg, PADP 10 mmHg), and left ventricular systolic function recovered completely.
  • Lactate levels significantly decreased from 11.0 mmol/L to 1.2 mmol/L.
  • Successful weaning from ECMO and pressor support within 24 hours of percutaneous coronary intervention, with discharge on day 6 and sustained recovery at 26-month follow-up.

Implications:

  • This case demonstrates the successful application of a combined ECMO, percutaneous coronary intervention, and hypothermia protocol for managing AMI with cardiogenic shock and refractory VF.
  • The presented treatment algorithm offers a favorable approach for similar high-risk cardiac emergencies.
  • Early implementation of mechanical circulatory support and timely revascularization can lead to significant recovery and improved long-term prognosis.

Related Concept Videos

Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
924
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
764
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
720